The findings of Grcevic et al. suggest that BMPs enhance the survival of myeloma cells by activating the ID family of oncogenes and hence increasing the balance between pro-survival and pro-apoptotic molecules. The gene discussed is CLN5; the disease is plasma cell myeloma.